ATE135587T1 - Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus) - Google Patents

Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus)

Info

Publication number
ATE135587T1
ATE135587T1 AT92903897T AT92903897T ATE135587T1 AT E135587 T1 ATE135587 T1 AT E135587T1 AT 92903897 T AT92903897 T AT 92903897T AT 92903897 T AT92903897 T AT 92903897T AT E135587 T1 ATE135587 T1 AT E135587T1
Authority
AT
Austria
Prior art keywords
igf
combination
igfbp
mammal
anabolism
Prior art date
Application number
AT92903897T
Other languages
English (en)
Inventor
Ross G Clark
Venkat R Mukku
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24624851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE135587(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE135587T1 publication Critical patent/ATE135587T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743Insulin-like growth factor binding protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92903897T 1991-02-12 1992-01-13 Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus) ATE135587T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/654,436 US5187151A (en) 1991-02-12 1991-02-12 Use of binding protein with igf-i as an anabolic growth promoting agent

Publications (1)

Publication Number Publication Date
ATE135587T1 true ATE135587T1 (de) 1996-04-15

Family

ID=24624851

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903897T ATE135587T1 (de) 1991-02-12 1992-01-13 Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus)

Country Status (10)

Country Link
US (1) US5187151A (de)
EP (1) EP0571417B1 (de)
JP (1) JPH06505235A (de)
AT (1) ATE135587T1 (de)
CA (1) CA2101340C (de)
DE (1) DE69209277T2 (de)
DK (1) DK0571417T3 (de)
ES (1) ES2085001T3 (de)
GR (1) GR3019851T3 (de)
WO (1) WO1992013556A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
JPH08500827A (ja) * 1992-08-26 1996-01-30 セルトリックス ファーマシューティカルズ,インコーポレイテッド 異化症状および全身性組織創傷の全身的治療方法
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
ES2095086T3 (es) * 1992-10-29 1997-02-01 Genentech Inc Metodo para el tratamiento y la prevencion de la obesidad.
ES2174868T3 (es) * 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
JPH09500088A (ja) * 1993-01-29 1997-01-07 アムジェン ボールダー インコーポレイテッド 創傷治癒用組成物
US5459051A (en) * 1993-03-26 1995-10-17 Celtrix Pharmaceuticals, Inc. Methods and vectors for over-expression of ubiquitin fusion proteins in host cells
WO1995008567A1 (en) * 1993-09-20 1995-03-30 Celtrix Pharmaceuticals, Inc. Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
JPH09509140A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ,インコーポレイテッド 神経学的障害の治療方法
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
AU713275B2 (en) * 1994-07-20 1999-11-25 Celtrix Pharmaceuticals, Inc. IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AUPN271195A0 (en) * 1995-05-02 1995-05-25 Bunge Meat Industries Ltd. Method of selecting livestock
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0766966A3 (de) * 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5747273A (en) * 1996-05-07 1998-05-05 Diagnostic Systems Laboratories, Inc. Immunoassay of total insulin-like growth factor binding protein-1
AUPN999096A0 (en) * 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6066464A (en) * 1996-12-10 2000-05-23 Diagnostic Systems Laboratories, Inc. Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots
US5824467A (en) * 1997-02-25 1998-10-20 Celtrix Pharmaceuticals Methods for predicting drug response
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
DE69835878T2 (de) * 1997-05-05 2007-04-26 Mayo Foundation For Medical Education And Research, Rochester IGFIIE/ IGFBP2 Komplex
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
CA2345642A1 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
DK1141014T3 (da) * 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
HUP0500733A3 (en) * 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
CA2460719A1 (en) * 2001-09-18 2003-03-27 Bioexpertise, Llc Igf-binding protein-derived peptide or small molecule
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
NZ553057A (en) * 2004-08-30 2009-12-24 Tercica Inc Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
EP2148695B1 (de) * 2007-04-18 2014-10-15 Premacure AB Verfahren und produkt zur behandlung und/oder vorbeugung von komplikationen in zusammenhang mit frühgeburten
WO2017117236A1 (en) * 2015-12-31 2017-07-06 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
US10212614B2 (en) * 2015-12-31 2019-02-19 Facebook, Inc. Igniting network nodes in a multi-hop wireless network

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1163880B (it) * 1983-07-29 1987-04-08 Guido Vergari Fascetta di legatura
US5077276A (en) * 1985-08-22 1991-12-31 Gropep Pty Ltd Growth factor
AU627423B2 (en) * 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
JPH03504597A (ja) * 1988-04-12 1991-10-09 シナージェン,インコーポレーテッド インスリン様成長因子活性の強化および阻害方法
DE3822646A1 (de) * 1988-07-05 1990-01-11 Steag Ag Verfahren zur gewinnung von sphaerischen feststoffteilchen insbesondere solchen zur verwendung als strahlperlen
CA1341598C (en) * 1988-07-15 2009-09-29 Central Sydney Area Health Service Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides

Also Published As

Publication number Publication date
CA2101340C (en) 2003-05-06
JPH06505235A (ja) 1994-06-16
WO1992013556A1 (en) 1992-08-20
DE69209277T2 (de) 1996-10-31
EP0571417B1 (de) 1996-03-20
EP0571417A1 (de) 1993-12-01
DK0571417T3 (da) 1996-04-15
CA2101340A1 (en) 1992-08-13
ES2085001T3 (es) 1996-05-16
US5187151A (en) 1993-02-16
GR3019851T3 (en) 1996-08-31
DE69209277D1 (de) 1996-04-25

Similar Documents

Publication Publication Date Title
ATE135587T1 (de) Kombination von igf-i und igfbp für den aufbaustoffwechsel (anabolismus)
CA2083159A1 (en) The combination of growth hormone and insulin-like growth factor-1 enhances growth
DE69219607D1 (de) Verfahren zur anregung der immunresponz
Dempsey et al. The experimental induction of oestrus (sexual receptivity) in the normal and ovariectomized guinea pig
MD1558F2 (en) Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor
FI20050467A (fi) Menetelmiä kasvuhormonin vapautumisen edistämieksi eläimessä
DE3687551D1 (de) Implantate mit verzoegerter abgabe fuer die anwendung von rekombinanten wachstumshormonen.
IT1197570B (it) Miscele di fsh e lh da ipofisi porcine in rapporto definito
SE9100242D0 (sv) Saett att mjoelka
ATE343395T1 (de) Verfahren zur verabreichung von igf-1
Singhas et al. Hormonal control of the tail fin and of the nuptial pads in the male red-spotted newt
Dubreuil et al. Influence of age and sex on basal secretion of growth hormone (GH) and on GH-induced release by porcine GH-releasing factor pGRF (1–29NH2) in growing pigs
ES2174838T3 (es) Metodo para aumentar la absorcion del intestino.
AR004124A1 (es) Proceso para la preparacion de un secretagogo de hormona de crecimiento.
DE69417397T2 (de) Lösung, die igf-1 enthält
O’Callaghan et al. Effect of exogenous thyroxine on timing of seasonal reproductive transitions in ewes
NZ219530A (en) Composition and method for enhancing growth of mammary parenchyma
MY100892A (en) Veterinary preparations.
DE69131629D1 (de) Behandlung fehlender milchabsonderung beim menschen
DE69220229D1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
ES2097816T5 (es) Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.
AU6461590A (de)
Cushman et al. Use of slow-release estradiol and prostaglandin F2α to induce pseudopregnancy and control estrus in gilts
Lamond Controlled breeding in sheep: Gordon, I. Irish Vet. J. 28: 118–126, 1974. Department of Farm Management, University College, Dublin, Lyons, Newcastle, County Dublin, Ireland
RU93051204A (ru) Способ профилактики задержания последа у коров

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time